The timing of continuous dopaminergic stimulation (CDS) treatment is an important consideration for achieving optimal motor functioning in Parkinson's disease patients. Delaying treatment with levodopa/carbidopa intestinal gel (LCIG) infusion in patients with severe 'on-off' fluctuations may result in a poorer and slower response, while early initiation of CDS therapy increases the chance of achieving continuous 'on' without dyskinesia. Furthermore, overnight LCIG infusion is indicated when there is severe akinesia overnight, but daytime-only LCIG infusion treatment can lead to a reduction in overnight motor fluctuations after several months.
The timing of continuous dopaminergic stimulation (CDS) therapy is an important consideration in achieving the most favourable motor outcomes. According to the official product information in Germany, levodopa/carbidopa intestinal gel (LCIG) infusion should be used for the 'treatment of advanced, levodopa-responsive Parkinson's disease with severe motor fluctuations AND hyper-/dyskinesia when available antiparkinsonian treatment is not satisfying anymore'. 1 In Germany, younger patients without cognitive impairments are more likely to receive deep brain stimulation (DBS), while older patients with cognitive impairments are more likely to receive LCIG infusion therapy. In addition, there is a tendency in Germany for DBS to be performed when there is only 'wearing off' in patients, while LCIG infusion treatment is not initiated before there are more severe motor fluctuations including hyperkinesia. An interesting question is whether this approach to use LCIG treatment later in the course of the disease compared with DBS is optimal. Two patient cases are presented here to illustrate the effects of starting LCIG infusion at different stages of Parkinson's disease (PD), and the effects of daytime-only LCIG infusion on overnight motor fluctuations.
Case Reports

Baseline Motor Performance
Two patient cases are presented and these are referred to as 'Patient 1' and 'Patient 2'. Patient 1 is a man in his early 60s who experienced severe motor fluctuations. Sometimes he only had good motor 'on' for about 20 % of the day and was either 'off' or 'on with severe dyskinesia' for the remainder of the day. He sometimes shifted from 'on' with severe dyskinesia directly to the 'off' phase, and had very difficult nights with severe 'off' phases (see Table 1A ). Patient 1 had depression, cognitive impairment and slight hallucinations, and was taking the following medications when he first presented at our department: levodopa 200 mg every three hours (six times daily), entacapone 200 mg every three hours (six times daily), amantadine 200 mg twice daily, cabergoline 4 mg once daily and levodopa at request (up to 600 mg a day). Most of the levodopa at request was taken at night to treat severe night-time 'off' phases. He also took mirtazapine 15 mg in the evening and escitalopram 10 mg in the morning for his depression, and quetiapine 25 mg in the evening for his hallucinations.
Patient 2 is a man in his late 60s, and suffered from motor fluctuations, moving between 'off' and 'on' phases, with no dyskinesia (see Table 2A ). He was taking levodopa 100-150 mg every 2.5 hours, levodopa slow-release 200 mg at night and rotigotine 4 mg (a higher dose was not possible because of orthostatic problems). He could not be treated with entacapone or tolcapone because of severe diarrhoea, and other dopamine agonists were not tolerated because of orthostatic problems. In addition, further increases in levodopa dosage
were not tolerated due to severe orthostatic hypotension. Despite his medications, the patient was still experiencing 'off' phases.
Furthermore, he had severe night-time cramping that did not respond to levodopa, magnesium or quinine treatment.
Sharing Experience in the Management of Advancing Parkinson's Disease 
Early versus Delayed Initiation of Levodopa/Carbidopa Intestinal Gel Infusion Treatment
LCIG infusion therapy was considered as a treatment option for these two patients. Patient 1 was also considered for DBS, but there was a higher risk of side effects due to his cognitive impairments and depression.
Thus, after discussion of his treatment options, the patient decided to go for LCIG treatment. Patient 2 was primarily considered for DBS but he refused brain operation and was therefore offered LCIG infusion.
The issue was, would LCIG infusion treatment be meaningful for these patients, and if it was, should it be started immediately or Table 1B ). However, he already felt better and decided to go for percutaneous endoscopic gastrostomy surgery. At discharge from hospital, his effective LCIG morning dose -i.e., after filling of percutaneous endoscopic jejunostomy tubing -was 10 ml. His LCIG infusion was at a continuous rate of 6.8 ml/h, with an extra dose of 4 ml.
The patient was advised to only take extra doses when absolutely required, and over the coming months he was very restrictive in this respect and only applied a maximum of one extra dose per day, even though the severity of frequent 'off' phases would have necessitated more. After one month, there was increased time spent in the 'on' phase and less severe hyperkinesias in the morning (see Table 1C ).
However, the fluctuations were still severe in the afternoon, and there remained many 'off' phases during the night. After three months, 'on' phases increased, but there were still profound motor fluctuations (see Table 1D ). Furthermore, the nights remained difficult. Only after six months of LCIG infusion treatment did the patient report a substantial change: he experienced 'on' with slight or no dyskinesia for most of the morning and afternoon (see Table 1E ). The nights improved and the patient did not experience severe night-time akinesia anymore. He was able to go to the bathroom at night, which had not been possible before due to akinesia, and during most nights he was able to sleep continuously without waking up due to severe 'off' phases. This situation has now remained stable for more than 2.5 years after initiation of LCIG infusion treatment.
Motor Performance of Patient 2 Over Time
In contrast, after only five days of treatment with LCIG infusion, Patient 2 was in the 'on' phase continuously, with no hyperkinesias (see Table 2B ). At discharge from hospital, his effective morning dose was 4 ml, the continuous rate was 3.8 ml/h and he did not require any extra doses. A good response to LCIG treatment was maintained at one month, with only 30 minutes of 'off' time a day (see Table 2C ).
This situation has now been stable for more than one year after the start of LCIG infusion treatment. The patient has a maximum of two hours of 'off' periods during the day, but these are much less severe than before LCIG treatment and do not require an extra LCIG dose. Table 1A ). The medication reduced the severity of the night-time 'off'
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phases, but they were still present and sleep was severely disturbed Table 1C ). The possibility to perform 24-hour LCIG infusion was discussed with the patient, but he decided to continue with daytime treatment only. After three months, sleep remained very disturbed, but the patient reported that 'off' phases felt a little less severe and he needed 'only' 400 mg levodopa overnight (200 mg at 01:00
and 03:00 -see Table 1D ). After six months, overnight levodopa was no longer required and the patient was able to sleep through the night (see Table 1E ). At the same time, his daytime motor fluctuations were largely eliminated. He has not needed overnight levodopa up to now, after more than 2.5 years of LCIG infusion treatment.
Although continuation of LCIG infusion treatment overnight is indicated when there is severe akinesia at night, we have observed in Patient 1 and in two other patients that, several months after starting daytime-only LCIG infusion treatment, overnight motor fluctuations subsided. This suggests that there is plasticity in the brain that requires some months to fully develop and that treatment may thus take some months to exert its full effect.
It has been shown in an animal model of PD that CDS by intracerebral gene therapy normalises mRNA expression of critical genes in the brain in parallel with improving motor behaviours and dyskinesia (see Figure 1 ). 4 The study used animals with the equivalent of late-stage PD that were having severe motor fluctuations -i.e., comparable to Patient 1 -and the full motor effect and reduction of dyskinesia in these animals were not seen until three months into treatment. This plasticity in the brain, as seen in the animal model, may be the correlate to the motor improvement seen in our patients.
Overall Conclusion
The patient cases presented in this article illustrate the importance 
